Page 885 - Williams Hematology ( PDFDrive )

860 Part VI: The Erythrocyte Chapter 55: Alloimmune Hemolytic Disease of the Fetus and Newborn 861

24. Pasman SA, Sikkel E, Le Cessie S, et al: Bilirubin/albumin ratios in fetal blood and in 58. Grant SR, Kilby MD, Meer L, et al: The outcome of pregnancy in Kell alloimmunisation.
amniotic fluid in rhesus immunization. Obstet Gynecol 111(5):1083, 2008. BJOG 107(4):481, 2000.
25. Janssens HM, de Haan MJ, van Kamp IL, et al: Outcome for children treated with 59. Kamphuis MM, Lindenburg I, van Kamp IL, et al: Implementation of routine screening
fetal intravascular transfusions because of severe blood group antagonism. J Pediatr for Kell antibodies: Does it improve perinatal survival? Transfusion 48(5):953, 2008.
131(3):373, 1997. 60. McKenna DS, Nagaraja HN, O’Shaughnessy R: Management of pregnancies compli-
26. Shapiro SM: Definition of the clinical spectrum of kernicterus and bilirubin-induced cated by anti-Kell isoimmunization. Obstet Gynecol 93(5 Pt 1):667, 1999.
neurologic dysfunction (BIND). J Perinatol 25(1):54, 2005. 61. Bowman JM, Pollock JM, Manning FA, et al: Maternal Kell blood group alloimmuniza-
27. Kuzniewicz M, Newman TB: Interaction of hemolysis and hyperbilirubinemia on tion. Obstet Gynecol 79(2):239, 1992.
neurodevelopmental outcomes in the collaborative perinatal project. Pediatrics 62. Vaughan JI, Manning M, Warwick RM, et al: Inhibition of erythroid progenitor cells by
123(3):1045, 2009. anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 338(12):798, 1998.
28. Nicolaides KH: Studies on fetal physiology and pathophysiology in rhesus disease. 63. Wagner T, Bernaschek G, Geissler K: Inhibition of megakaryopoiesis by Kell-related
Semin Perinatol 13(4):328, 1989. antibodies. N Engl J Med 343(1):72, 2000.
29. Smits-Wintjens VE, Rath ME, Lindenburg IT, et al: Cholestasis in neonates with red 64. Wagner T, Resch B, Reiterer F, et al: Pancytopenia due to suppressed hematopoiesis in
cell alloimmune hemolytic disease: incidence, risk factors and outcome. Neonatology a case of fatal hemolytic disease of the newborn associated with anti-K supported by
101(4):306, 2012. molecular K1 typing. J Pediatr Hematol Oncol 26(1):13, 2004.
30. Rath ME, Smits-Wintjens VE, Oepkes D, et al: Thrombocytopenia at birth in neonates 65. Sarici SU, Yurdakök M, Serdar MA, et al: An early (sixth-hour) serum bilirubin mea-
with red cell alloimmune haemolytic disease. Vox Sang 102(3):228, 2012. surement is useful in predicting the development of significant hyperbilirubinemia and
31. Smits-Wintjens VE, Walther FJ, Lopriore E: Rhesus haemolytic disease of the newborn: severe ABO hemolytic disease in a selective high-risk population of newborns with
Postnatal management, associated morbidity and long-term outcome. Semin Fetal Neo- ABO incompatibility. Pediatrics 109(4):e53, 2002.
natal Med 13(4):265, 2008. 66. Lin M, Broadberry RE: ABO hemolytic disease of the newborn is more severe in Tai-
32. Blanco E, Johnston DL: Neutropenia in infants with hemolytic disease of the newborn. wan than in white populations. Vox Sang 68(2):136, 1995.
Pediatr Blood Cancer 58(6):950, 2012. 67. Miqdad AM, Abdelbasit OB, Shaheed MM, et al: Intravenous immunoglobulin G
33. Lobato G, Soncini CS: Relationship between obstetric history and Rh(D) alloimmuni- (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the
zation severity. Arch Gynecol Obstet 277(3):245, 2008. newborn. J Matern Fetal Neonatal Med 16(3):163, 2004.
34. Katz MA, Kanto WP Jr, Korotkin JH: Recurrence rate of ABO hemolytic disease of the 68. Kaplan M, Hammerman C, Renbaum P, et al: Gilbert’s syndrome and hyperbilirubi-
newborn. Obstet Gynecol 59(5):611, 1982. naemia in ABO-incompatible neonates. Lancet 356(9230):652, 2000.
35. Kleinman S: Hemolytic disease of the newborn: RBC alloantibodies in pregnancy 69. Pirelli KJ, Pietz BC, Johnson ST, et al: Molecular determination of RHD zygosity: Pre-
and associated serologic issues. UpToDate 2014. http://www.uptodate.com/contents/ dicting risk of hemolytic disease of the fetus and newborn related to anti-D. Prenat
hemolytic-disease-of-the-newborn-rbc-alloantibodies-in-pregnancy-and-associated- Diagn 30(12-13):1207, 2010.
serologic-issues. Last accessed on June 20, 2014. 70. Blood Center of Wisconsin Diagnostics: RhD Zygosity Testing. 2014. Available from:
36. Barss VA, Moise KJ Jr: Significance of minor red blood cell antibodies during pregnancy. https://www.bcw.edu/cs/groups/public/documents/documents/mdaw/mdaz/~edisp/
UpToDate 2014. http://www.uptodate.com/contents/significance-of-minor-red-blood- rhd_zygosity_desc.pdf. Last accessed on May 29, 2015.
cell-antibodies-during-pregnancy. Last accessed on June 20, 2014. 71. Lo YM, Bowell PJ, Selinger M, et al: Prenatal determination of fetal RhD status by anal-
37. Flegel WA: Molecular genetics of RH and its clinical application. Transfus Clin Biol ysis of peripheral blood of rhesus negative mothers. Lancet 341(8853):1147, 1993.
13(1–2):4, 2006. 72. Geifman-Holtzman O, Grotegut CA, Gaughan JP: Diagnostic accuracy of noninva-
38. Denomme GA, Wagner FF, Fernandes BJ, et al: Partial D, weak D types, and novel RHD sive fetal Rh genotyping from maternal blood—A meta-analysis. Am J Obstet Gynecol
alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization 195(4):1163, 2006.
and prevention. Transfusion 45(10):1554, 2005. 73. Daniels G, Finning K, Martin P, Massey E: Noninvasive prenatal diagnosis of fetal blood
39. Avent ND, Reid ME: The Rh blood group system: A review. Blood 95(2):375, 2000. group phenotypes: Current practice and future prospects. Prenat Diagn 29(2):101,
40. Shirey RS, Mirabella DC, Lumadue JA, Ness PM: Differentiation of anti-D, -C, and -G: 2009.
clinical relevance in alloimmunized pregnancies. Transfusion 37(5):493, 1997. 74. Geifman-Holtzman O, Grotegut CA, Gaughan JP, et al: Noninvasive fetal RhCE geno-
41. Bowman JM, Pollock JM, Penston LE: Fetomaternal transplacental hemorrhage during typing from maternal blood. BJOG 116(2):144, 2009.
pregnancy and after delivery. Vox Sang 51(2):117, 1986. 75. Bombard AT, Akolekar R, Farkas DH, et al: Fetal RHD genotype detection from circu-
42. Sebring ES, Polesky HF: Fetomaternal hemorrhage: incidence, risk factors, time of lating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women.
occurrence, and clinical effects. Transfusion 30(4):344, 1990. Prenat Diagn 31(8):802, 2011.
43. Ness PM, Baldwin ML, Niebyl JR: Clinical high-risk designation does not predict 76. Moise KJ Jr: Management of rhesus alloimmunization in pregnancy. Obstet Gynecol
excess fetal-maternal hemorrhage. Am J Obstet Gynecol 156(1):154, 1987. 112(1):164, 2008.
44. Pourbabak S, Rund CR, Crookston KP: Three cases of massive fetomaternal hemor- 77. Gooch A, Parker J, Wray J, Qureshi H: Guideline for blood grouping and antibody
rhage presenting without clinical suspicion. Arch Pathol Lab Med 128(4):463, 2004. testing in pregnancy. Transfus Med 17(4):252, 2007.
45. Jansen MW, Brandenburg H, Wildschut HI, et al: The effect of chorionic villus sam- 78. Adeniji AA, Fuller I, Dale T, Lindow SW: Should we continue screening rhesus D posi-
pling on the number of fetal cells isolated from maternal blood and on maternal serum tive women for the development of atypical antibodies in late pregnancy? J Matern Fetal
alpha-fetoprotein levels. Prenat Diagn 17(10):953, 1997. Neonatal Med 20(1):59, 2007.
46. Bowman JM, Pollock JM: Transplacental fetal hemorrhage after amniocentesis. Obstet 79. Hadley AG: Laboratory assays for predicting the severity of haemolytic disease of the
Gynecol 66(6):749, 1985. fetus and newborn. Transpl Immunol 10(2–3):191, 2002.
47. Bowman JM, Pollock JM, Peterson LE, et al: Fetomaternal hemorrhage following funi- 80. Daffos F, Capella-Pavlovsky M, Forestier F: Fetal blood sampling during pregnancy
puncture: increase in severity of maternal red-cell alloimmunization. Obstet Gynecol with use of a needle guided by ultrasound: A study of 606 consecutive cases. Am J
84(5):839, 1994. Obstet Gynecol 153(6):655, 1985.
48. Urbaniak SJ: Alloimmunity to RhD in humans. Transfus Clin Biol 13(1–2):19, 2006. 81. Queenan JT, Tomai TP, Ural SH, King JC: Deviation in amniotic fluid optical density at
49. Cid J, Lozano M: Risk of Rh(D) alloimmunization after transfusion of platelets from D+ a wavelength of 450 nm in Rh-immunized pregnancies from 14 to 40 weeks’ gestation:
donors to D- recipients. Transfusion 45(3):453; author reply 453, 2005. A proposal for clinical management. Am J Obstet Gynecol 168(5):1370, 1993.
50. Bowman J, Harman C, Manning F, et al: Intravenous drug abuse causes Rh immuniza- 82. Dukler D, Oepkes D, Seaward G, et al: Noninvasive tests to predict fetal anemia: a study
tion. Vox Sang 61(2):96, 1991. comparing Doppler and ultrasound parameters. Am J Obstet Gynecol 188(5):1310,
51. Kumpel BM: On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. 2003.
Transfusion 46(9):1652, 2006. 83. Buscaglia M, Ghisoni L, Bellotti M, et al: Percutaneous umbilical blood sampling: indi-
52. Bowman JM: Fetomaternal AB0 incompatibility and erythroblastosis fetalis. Vox Sang cation changes and procedure loss rate in a nine years’ experience. Fetal Diagn Ther
50(2):104, 1986. 11(2):106, 1996.
53. Neppert J, v Witzleben-Schürholz E, Zupanska B, et al: High incidence of maternal 84. Ghidini A, Sepulveda W, Lockwood CJ, Romero R: Complications of fetal blood sam-
HLA A, B and C antibodies associated with a mild course of haemolytic disease of the pling. Am J Obstet Gynecol 168(5):1339, 1993.
newborn. Group for the Study of Protective Maternal HLA Antibodies in the Clinical 85. Oepkes D, Seaward PG, Vandenbussche FP, et al: Doppler ultrasonography versus
Course of HDN. Eur J Haematol 63(2):120, 1999. amniocentesis to predict fetal anemia. N Engl J Med 355(2):156, 2006.
54. Palfi M, Hildén JO, Gottvall T, Selbing A: Placental transport of maternal immunoglob- 86. Mari G, Deter RL, Carpenter RL, et al: Noninvasive diagnosis by Doppler ultrasonogra-
ulin G in pregnancies at risk of Rh (D) hemolytic disease of the newborn. Am J Reprod phy of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for
Immunol 39(5):323, 1998. Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 342(1):9, 2000.
55. Lambin P, Debbia M, Puillandre P, Brossard Y: IgG1 and IgG3 anti-D in maternal serum 87. Oepkes D, Adama van Scheltema P: Intrauterine fetal transfusions in the management
and on the RBCs of infants suffering from HDN: Relationship with the severity of the of fetal anemia and fetal thrombocytopenia. Semin Fetal Neonatal Med 12(6):432, 2007.
disease. Transfusion 42(12):1537, 2002. 88. Howe DT, Michailidis GD: Intraperitoneal transfusion in severe, early-onset Rh isoim-
56. Eder AF: Update on HDFN: New information on long-standing controversies. Immu- munization. Obstet Gynecol 110(4):880, 2007.
nohematol 22(4):188, 2006. 89. Fox C, Martin W, Somerset DA, et al: Early intraperitoneal transfusion and adjuvant
57. Kennedy M: Perinatal issues in transfusion practice, in Technical Manual, edited by J maternal immunoglobulin therapy in the treatment of severe red cell alloimmunization
Roback, M Combs, B Grossman. AABB Press, Bethesda, MD, 2008. prior to fetal intravascular transfusion. Fetal Diagn Ther 23(2):159, 2008.

Kaushansky_chapter 55_p0847-0862.indd 860 9/18/15 11:53 PM